Skip to main content
Premium Trial:

Request an Annual Quote

Tammy Mullarky, Peter Lutwyche, John Schmidt, Victor Kotelianski, Antonin de Fougerolles, Susanna High, Dinah Sah, Bryan Dunnivant

Premium
Tekmira Pharmaceuticals has named Tammy Mullarky as its vice president of strategic planning and business development, and Peter Lutwyche as vice president of pharmaceutical development.
 
Mullarky previously served as senior vice president of crop biotechnology firm Targeted Growth. Before that, she was a senior executive at Epigenomics, a cancer molecular diagnostics company.
 
She holds an MA in science management from the Massachusetts Institute of Technology and a BA in chemistry from Whitman College.
 
Lutwyche was formerly with Protiva Biotherapeutics, which merged with Tekmira earlier this year (see RNAi News, 4/3/2008). Before that, he held a number of positions, most recently director of pharmaceutical development, at QLT.
 
He holds a PhD in chemistry from the University of British Columbia.
 

 
Alnylam Pharmaceuticals has named John Schmidt as its CSO.
 
Schmidt was previously vice president and US member of the Sanofi-Aventis Global Discovery Leadership Team. Prior to Aventis’ merger with Sanofi-Synthelabo, Schmidt was Aventis’ vice president and head of the respiratory and rheumatoid arthritis disease group. He also served as senior director of immunology and rheumatology at Merck Research Laboratories.
 
Schmidt holds an MD from the University of Pennsylvania.
 
Alnylam also said it has promoted Victor Kotelianski to the newly created position of senior vice president and distinguished Alnylam fellow. He was previously vice president of research.
 
Additionally, the company has promoted Antonin de Fougerolles to the position of vice president of research, immunology, metabolic, and viral disease; Susanna High to the position of vice president of business planning and program management; and Dinah Sah to the position of vice president of research, CNS, and oncology.
 

 
Intradigm has appointed Bryan Dunnivant, a principal at investment group Lilly Ventures, to its board of directors.
 
Dunnivant is joining the board in connection with Lilly Ventures’ participation in Intradigm’s Series B financing round (see related story, this issue).

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.